What are the indications for plasma exchange (PLEX) treatment?

Indications for Plasma Exchange (PLEX) Treatment

Plasma exchange is indicated primarily for ANCA-associated vasculitis with severe kidney impairment (serum creatinine ≥500 μmol/L), thrombotic thrombocytopenic purpura (TTP), and as rescue therapy for steroid-refractory severe relapses in CNS inflammatory demyelinating diseases.

Primary Indications by Disease Category

ANCA-Associated Vasculitis (AAV)

Renal Involvement:

• Strongly indicated when serum creatinine ≥500 μmol/L with rapidly progressive glomerulonephritis 1
• Most guidelines (KDIGO 2020, EULAR/ERA-EDTA 2016, BSR/BHPR 2021) converge on this threshold
• KDIGO 2020 specifically recommends against routine use for GFR <50 mL/min/1.73 m² but supports consideration for severe presentations, especially if oliguric 1
• ASFA 2020 provides strong recommendation (moderate quality evidence) for creatinine ≥500 μmol/L as accepted second-line or adjuvant therapy 1

Important caveat: CanVasc 2016 diverges, recommending against PLEX as first-line therapy even with severe renal involvement, suggesting it only as adjuvant if patients clinically deteriorate 1. However, this represents the minority position among major guidelines.

Pulmonary Hemorrhage:

• Guidelines show significant divergence on this indication 1
• ASFA 2020 considers it Class I indication (first-line therapy) with strong recommendation despite low-quality evidence 1
• KDIGO 2020 and EULAR/ERA-EDTA 2016 favor PLEX for diffuse alveolar hemorrhage with hypoxemia 1
• BSR 2017 states insufficient evidence, noting PLEX only "possibly beneficial" 1
• Clinical approach: Given the high mortality risk of pulmonary hemorrhage, favor PLEX use despite mixed guideline consensus, particularly when hypoxemia is present

Thrombotic Thrombocytopenic Purpura (TTP)

PLEX is the cornerstone of treatment and must be initiated immediately upon clinical suspicion 2:

• Do not wait for ADAMTS13 activity results (turnaround time may be days)
• Historical randomized trial established TPE superiority over plasma infusions (mortality 4% vs 16%, P=0.035) 2
• Indicated for all TTP subtypes: immune TTP (iTTP), congenital TTP (cTTP), and TTP of unknown cause (uTTP) 2
• Critical pitfall: Delaying treatment while awaiting confirmatory testing increases mortality risk substantially

CNS Inflammatory Demyelinating Diseases

Multiple Sclerosis and Neuromyelitis Optica:

• Indicated as rescue therapy for severe relapses unresponsive to high-dose corticosteroids 3
• Recent data shows 73.8% of severe MS relapses demonstrate marked clinical improvement with PLEX 4
• Prognostic factors for poor response: Higher EDSS at nadir (OR=0.63) and older age (OR=1.07) 4
• Greater theoretical benefit in NMO due to prominent humoral mechanisms 3
• Key gap: Optimal timing remains unclear, but evidence suggests earlier initiation may improve outcomes 3

Additional Established Indications

Nephrology

• Goodpasture syndrome (anti-GBM disease) - well-established indication 5
• Acute humoral rejection post-renal transplant 5
• HLA desensitization protocols for transplantation 5
• Recurrent focal segmental glomerulosclerosis on transplant 5

Hematology

• Hyperviscosity syndrome 6
• Catastrophic antiphospholipid syndrome 6

Neurology

• Myasthenic crisis 6, 7
• Guillain-Barré syndrome (implied from general neurology indications) 3

Other Critical Indications

• Fulminant liver failure 6
• Wilson's disease with massive hemolysis 6
• Severe pancreatitis due to chylomicronemia 6
• Thyrotoxic crisis 6

Common Pitfalls to Avoid

1. Waiting for confirmatory tests in TTP: Start PLEX on clinical suspicion alone 2
2. Using PLEX as first-line for all AAV renal disease: Reserve for creatinine ≥500 μmol/L; below this threshold, individualize based on clinical deterioration 1
3. Inadequate immunosuppression: PLEX alone is insufficient; must combine with appropriate immunosuppressive therapy to prevent rebound 5
4. Delayed initiation in steroid-refractory CNS disease: Earlier treatment may improve outcomes 3

Safety Profile

Complications are relatively rare according to registry data 5. Most common adverse event is hypocalcemic reaction from citrate anticoagulation, which is readily preventable or treatable 8. Adverse events occurred in 17.3% of procedures in MS cohort but were completely resolved 4.